ArticleScience (New York, N.Y.)2022
Broadly neutralizing antibodies target the coronavirus fusion peptide.
Open access · hybridAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 188 papers.
0numbers the graph read from it
0cells of the map it votes in
188citing papers in PubMed
25.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
188 citing papers in PubMed, 263 citations in OpenAlex.
- Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines.Cell reports · 2025Trial
- Sequence-based artificial intelligence-guided inhibitory peptides to counteract AAV neutralizing antibodies in gene therapy.Molecular therapy. Advances · 2026Article
- Article
- Article
- Structural basis of diverse antibody recognition of conserved coronavirus spike S2 epitopes that contribute to protective immunity.bioRxiv : the preprint server for biology · 2026Article
- ACE2-like Catalytic Activity in Anti-SARS-CoV-2 Spike Protein Monoclonal Antibodies.Pathogens (Basel, Switzerland) · 2026Article
- A Synthetic Platform for Antibody Junctional Diversification Beyond Natural Constraints.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Structural and functional characterization of a conserved cryptic epitope on SARS-CoV-2 spike S2 subunit.PLoS pathogens · 2026Article
- The SARS-CoV-2 S2'-helix compared to stem helix confers higher genetic barrier to antibody resistance.PLoS pathogens · 2026Article
- Benchmarking AlphaFold and related deep learning approaches for modeling antibody and TCR antigen recognition.bioRxiv : the preprint server for biology · 2026Article
- A designed overlapping variant immunogen pool elicits broad sarbecovirus neutralization.bioRxiv : the preprint server for biology · 2026Article
- Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Viruses · 2026Review
- Article
- TMPRSS2-mediated coronavirus spike activation and inhibition.Nature structural & molecular biology · 2026Article
- Cryo-ET of IgG bivalent binding on SARS-CoV-2 provides structural basis for antibody avidity.Nature communications · 2026Article
- Monoclonal antibodies from COVID-19 convalescent patients target cryptic epitopes for broad SARS-CoV-2 neutralization.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Repeated COVID-19 vaccine boosters elicit variant-specific memory B cells in humans.Cell reports · 2026Article
- Conformational dynamics of SARS-CoV-2 spike on a membrane reveals the allosteric effects of furin cleavage and the D614G mutation.Science advances · 2026Article
- Pandemic-driven immune imprinting accelerates evolution of human coronavirus OC43.PLoS neglected tropical diseases · 2026Article
- SARS-CoV-2 fusion-peptide-directed antibodies are elicited by natural infection and can mediate broad sarbecovirus neutralization.Cell reports · 2026Article
128 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
44 authors at 5 institutions in 1 country.
Cherrelle Dacon *Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.ORCID 0000-0003-2347-2740
Courtney Tucker *Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.ORCID 0000-0001-8632-8952
Linghang Peng *Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-3600-2134
Chang-Chun D Lee *Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-5470-2484
Ting-Hui LinDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-0937-9972
Meng YuanDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-9754-4503
Yu CongIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Lingshu WangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-8404-4910
Lauren PurserAntibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Jazmean K WilliamsIntegral Molecular, Philadelphia, PA 19104, USA.ORCID 0000-0002-4587-142X
Chul-Woo PyoClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Ivan KosikCellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-5756-5182
Zhe HuCellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Ming ZhaoProtein Chemistry Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.ORCID 0000-0002-5700-2950
Divya MohanAntibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Andrew J R CooperAntibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.ORCID 0000-0003-4466-6755
Mary PetersonMalaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.ORCID 0000-0001-6848-8709
Jeff SkinnerMalaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.ORCID 0000-0001-5697-0442
Saurabh DixitIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Erin KollinsIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.ORCID 0000-0001-7684-4443
Louis HuzellaIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Donna PerryIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Russell ByrumIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Sanae LembirikIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.ORCID 0000-0002-7278-9392
David DrawbaughIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Brett EatonIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.ORCID 0000-0002-3060-2913
Yi ZhangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-8228-2560
Eun Sung YangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-3161-1624
Man ChenVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-9799-7817
Kwanyee LeungVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-8582-7597
Rona S WeinbergNew York Blood Center, Lindsley F. Kimball Research Institute, New York, NY 10065, USA.ORCID 0000-0002-4503-1295
Amarendra PeguVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-3564-6453
Daniel E GeraghtyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Edgar DavidsonIntegral Molecular, Philadelphia, PA 19104, USA.
Iyadh DouagiFlow Cytometry Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-3221-8667
Susan MoirB Cell Immunology Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-0163-6911
Jonathan W YewdellCellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-3826-1906
Connie SchmaljohnIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.ORCID 0000-0001-8852-5482
Peter D CromptonMalaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.ORCID 0000-0001-5629-0412
Michael R HolbrookIntegrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.ORCID 0000-0002-0824-2667
David NemazeeDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-4769-6311
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Ian A WilsonDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-6469-2419
Joshua TanAntibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.ORCID 0000-0002-6661-6372
National Institutes of Health · USScripps Research Institute · USFred Hutch Cancer Center · USIntegral Molecular (United States) · USNew York Blood Center · US
Funding
Integrated Research Facility at Fort DetrickZICAI009006 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DONAHUE, SARAH · 2019 to 2025
$332.9MInfectious Diseases Research Technologies Core - BethesdaZICAI001051 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHERRY, JAMES · 2009 to 2025
$226.1MA Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI KEITH O HODGSON · 2020 to 2026
$43.3MUser Training & OutreachP30GM138396 · NIGMS · UCHICAGO ARGONNE, LLC · PI ROBERT F. FISCHETTI · 2020 to 2026
$34.3MB-Cell Epitope Discovery and Mechanisms of Antibody Protection for ZIKV, MARV, VEEV Envelope Proteins 75N93019C00073 · NIAID · INTEGRAL MOLECULAR · PI DORANZ, BENJAMIN · 2019 to 2023
$7.5MGermline targeting influenza immunogensR01AI132317 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NEMAZEE, DAVID · 2017 to 2021
$7.0MHigh-resolution definition of B cell responses to HIV Env for immunogen designR01AI102766 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI LI, YUXING · 2013 to 2024
$6.6MHuman monoclonal antibodies against SARS-CoV-2ZIAAI001285 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI TAN, JOSHUA · 2020 to 2025
$4.9MNext Generation Broadly Neutralizing Antibodies to Clear HIV-1 ReservoirR01AI136756 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LI, QINGSHENG, LI, YUXING · 2019 to 2023
$3.9MEvolution of anti-filovirus B cell responses and mechanisms of protectionR01AI126587 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI AMAN, M JAVAD, LI, YUXING · 2017 to 2021
$3.7MAnti-flavivirus B cell response analysis to aid vaccine designR01AI175439 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Yuxing Li · 2023 to 2026
$3.1MCOVID-19 Instrumentation in the RTBZICAI001313 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHERRY, JAMES · 2020 to 2023
$2.6MNIAID NIH HHS 75N93019C00073NIAID NIH HHS HHSN272201800013CNIAID NIH HHS R01 AI102766NIAID NIH HHS R01 AI132317NIAID NIH HHS R01 AI175439NIAID NIH HHS R41 AI147929NIGMS NIH HHS P30 GM133894NIGMS NIH HHS P30 GM138396
Abstract
The potential for future coronavirus outbreaks highlights the need to broadly target this group of pathogens. We used an epitope-agnostic approach to identify six monoclonal antibodies that bind to spike proteins from all seven human-infecting coronaviruses. All six antibodies target the conserved fusion peptide region adjacent to the S2' cleavage site. COV44-62 and COV44-79 broadly neutralize alpha- and betacoronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants BA.2 and BA.4/5, albeit with lower potency than receptor binding domain-specific antibodies. In crystal structures of COV44-62 and COV44-79 antigen-binding fragments with the SARS-CoV-2 fusion peptide, the fusion peptide epitope adopts a helical structure and includes the arginine residue at the S2' cleavage site. COV44-79 limited disease caused by SARS-CoV-2 in a Syrian hamster model. These findings highlight the fusion peptide as a candidate epitope for next-generation coronavirus vaccine development.
Indexed as
Antibodies, MonoclonalAntibodies, ViralBroadly Neutralizing AntibodiesCOVID-19EpitopesSARS-CoV-2Spike Glycoprotein, CoronavirusCOVID-19 VaccinesHumansPeptidesProtein Conformation, alpha-HelicalProtein DomainsAntibodies, MonoclonalAntibodies, ViralBroadly Neutralizing AntibodiesCOVID-19 VaccinesEpitopesPeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.